MAIA Biotechnology Inc. (MAIA) - Cash Flow Conversion Efficiency
Based on the latest financial reports, MAIA Biotechnology Inc. (MAIA) has a cash flow conversion efficiency ratio of -0.191x as of March 2026. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($-5.31 Million) by net assets ($27.76 Million). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations. See MAIA Biotechnology Inc. net asset quality index to measure how much of total assets are equity-financed.
MAIA Biotechnology Inc. - Cash Flow Conversion Efficiency Trend (2019–2025)
This chart illustrates how MAIA Biotechnology Inc.'s cash flow conversion efficiency has evolved over time, based on yearly financial data. Explore MAIA cash flow to debt ratio to assess how comfortably operating cash covers total debt obligations.
MAIA Biotechnology Inc. Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of MAIA Biotechnology Inc. ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Asetek A/S
F:A31
|
0.018x |
|
APEX International Financial Engineering Res & Tech Co Ltd
TWO:5210
|
0.016x |
|
District Metals Corp
V:DMX
|
-0.027x |
|
Aerovate Therapeutics Inc
NASDAQ:AVTE
|
-0.032x |
|
Xchanging Solutions Limited
NSE:XCHANGING
|
0.045x |
|
J W Mays Inc
NASDAQ:MAYS
|
0.028x |
|
Nan Ren Hu Leisure Amusement Co Ltd
TWO:5905
|
0.004x |
|
Mediaco Holding Inc
NASDAQ:MDIA
|
0.001x |
Annual Cash Flow Conversion Efficiency for MAIA Biotechnology Inc. (2019–2025)
The table below shows the annual cash flow conversion efficiency of MAIA Biotechnology Inc. from 2019 to 2025. For the full company profile with market capitalisation and key ratios, see MAIA Biotechnology Inc. (MAIA) total market value.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2025-12-31 | $2.38 Million | $-18.84 Million | -7.932x | -83.57% |
| 2024-12-31 | $3.63 Million | $-15.70 Million | -4.321x | +84.22% |
| 2023-12-31 | $477.51K | $-13.07 Million | -27.373x | -1825.30% |
| 2022-12-31 | $8.51 Million | $-12.10 Million | -1.422x | -216.61% |
| 2021-12-31 | $9.18 Million | $-4.12 Million | -0.449x | -139.36% |
| 2020-12-31 | $-1.62 Million | $-1.84 Million | 1.141x | +196.58% |
| 2019-12-31 | $1.32 Million | $-1.57 Million | -1.181x | -- |
About MAIA Biotechnology Inc.
MAIA Biotechnology, Inc., together with its subsidiaries, a clinical-stage biopharmaceutical company, engages in the development of targeted immunotherapies for cancer. Its lead product Ateganosine, a telomere-targeting agent currently in clinical development to evaluate its activity in Non-Small Cell Lung Cancer (NSCLC). The company was incorporated in 2018 and is headquartered in Chicago, Illin… Read more